Neuro-Sys, a company that deals with pharmacological Contract Research Services specialising in the R&D and in vitro testing of molecules used to treat neurogenerative diseases in the Central Nervous System and Peripheral Nervous System, has launched its in vivo services, it was reported on Tuesday.

The investment is intended to enable the company to provide animal models and behavioural testing that uses digital tracking systems for the testing of candidate molecules, to its present in vitro, and to new customers.

Chief scientific officer, Noelle Callizot, said, 'We continue to conduct research to refine our knowledge of the pathological pathways and to develop our innovative in vitro models. At the same time, it's important that our in vivo activity validates and enhances our in vitro work, allowing our customers a seamless process in their drug development programmes.'